Ballantyne, Christie M.
Baylor College of Medicine
126 papers on CoChatORCID 0000-0002-6432-1730
Most cited papers
- Verified
Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT
Szarek, M., Bhatt, D., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Tardif, J. C., Ballantyne, C. M., Ketchum, S. B., Pineda, A. L., et al. (2023) · European Heart Journal
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 9
- Verified
Abstract 17120: ARO-ANG3, an investigational RNAi therapeutic, silences the expression of ANGPTL3 and decreases atherogenic lipoproteins in patients with mixed dyslipidemia: ARCHES-2 study results
Watts, G. F., Gaudet, D., ALTAMIRANO, D., Hegele, R., Ballantyne, C. M., Nicholls, S., Chang, T., Alagarsamy, S., Fu, R., San Martin, J., et al. (2023) · Circulation
Lipid metabolism and disordersLipoproteins and Cardiovascular Health
Cited by 9
- Verified
Predicted Risk, Preclinical Heart Failure Measures, and Incident Heart Failure
Grant, J. K., Zhang, S., Khan, S. S., Ozkan, B., Blumer, V., Nambi, V., Echouffo-Tcheugui, J. B., Pandey, A., Blumenthal, R. S., Ballantyne, C. M., et al. (2025) · JACC: Heart Failure
Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors
Cited by 8
- Verified
N-acetylaspartate from fat cells regulates postprandial body temperature
Felix, J. B., Saha, P. K., de Groot, E. L., Tan, L., Sharp, R., Anaya, E. S., Li, Y., Quang, H., Saidi, N., Abushamat, L., et al. (2025) · Nature Metabolism
Adipose Tissue and MetabolismAdipokines, Inflammation, and Metabolic Diseases
Cited by 6
- Verified
Plozasiran (ARO-APOC3), an investigational RNAi, demonstrates robust and durable TG reductions in patients with mixed dyslipidemia, MUIR final results
Vasas, S., Azizad, M., Clifton, P., Rosenson, R., Gaudet, D., Hellawell, J., Chang, T., Melquist, S., Fu, R., Mushin, M., et al. (2024) · Journal of Clinical Lipidology
Lipoproteins and Cardiovascular HealthLipid metabolism and disorders
Cited by 3
- Verified
Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM
Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Pineda, A. L., Tardif, J.-C., & Ballantyne, C. M. (2026) · American Journal of Preventive Cardiology
Fatty Acid Research and HealthLipoproteins and Cardiovascular Health
Cited by 0
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free